Field Evaluation of a Human Anthrax Vaccine - Wikidata - wikimedia - TriplyDB

Field Evaluation of a Human Anthrax Vaccine

Field Evaluation of a Human Anthrax Vaccine

http://www.wikidata.org/entity/Q24554499

about

Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins Anthrax vaccine and public health policy Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin Genomic copy number variants: evidence for association with antibody response to anthrax vaccine adsorbed Conference report on public health and clinical guidelines for anthrax Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed Anthrax vaccination strategies Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines Identification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation.Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge The seminal literature of anthrax research.Anthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.Bacillus anthracis: medical issues of biologic warfare.Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis.Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen Search for correlates of protective immunity conferred by anthrax vaccine.Early statistical detection of anthrax outbreaks by tracking over-the-counter medication sales.New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.Provider and health care system response to a bioterrorist attack.Toxicological assessments of Gulf War veterans.Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).Development of an improved vaccine for anthrax Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine.Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak A Comparison of the Adaptive Immune Response between Recovered Anthrax Patients and Individuals Receiving Three Different Anthrax Vaccines.Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen.Effect of CpG oligonucleotides on vaccine-induced B cell memory.

P2860

Q24562788-B9F1D798-3F5B-4B58-9CBC-AF2B9037841C Q24675688-B6462E8F-3692-4D3F-A748-F6333385429D Q24796044-350EA0C1-7556-4A61-A748-DCC786615047 Q28383704-8C0EF671-56B2-4A24-BF5F-6C57DEE12C67 Q28386084-24CC8A9B-62F0-4501-800F-9C8C0893C78A Q28391301-E7BC36C0-052D-4633-98B5-3CC58C3CF230 Q28391462-38C44C05-EB87-434B-986F-7A2AB436C7EE Q28392248-D4DA84C0-ABC6-497E-8C51-8FF9E97D15C5 Q28398013-85CD27F9-F583-44F4-B475-4A6C5D307D5E Q30540217-8B2036AD-F973-46F7-9966-A879DD16F2D3 Q30638627-880E415E-E1FE-4F6B-AEA6-93DE5B64FD72 Q30651835-316AAA70-34EF-42A5-9D28-578882B30A90 Q31126626-468921E8-49A8-4CAD-A257-00997EF0EEF4 Q33222054-E92A5272-1F89-4BDA-943D-D28E97B03848 Q33284583-9F8EB74B-E8FD-40C5-9CA7-8ADFAF05FEC6 Q33291819-198C1C60-91B7-4B8D-A0FD-A1E3C6BE885C Q33505445-354BE0FC-A1FF-46C0-8490-4FF61C47F8D1 Q33677543-CC105B95-959A-4659-BEC8-3D673545523B Q33696203-6CFE66D1-054C-4CA6-A181-1863493E5072 Q33713243-C9984214-B7F7-4AEF-88CD-3F252BCB4316 Q33747721-AD546F17-84E4-489C-A791-0F38670FDD49 Q33756961-E09A8AA4-99C6-4287-9253-A72AD96A69EC Q33883273-82D0C050-D69F-4935-BB97-B54FA3F58EC2 Q34000174-9C6668EF-5F71-4DC4-B66B-65F63D29A487 Q34007168-9255BC40-59A8-4F5A-85A2-EA9CEC1EC861 Q34024159-CA1C5D8A-90E3-4A1A-8700-C88F0DCDB139 Q34066161-D9C294F3-C798-4E8E-903E-782C00CBF5DA Q34108313-4B4A36F7-C79F-43AC-B536-CE75E98CF5AC Q34191394-E4D78A9C-37A8-4521-8086-0D2AA01A1B28 Q34524009-7F208D3B-AB94-4DEC-9186-AB33F2C8622E Q34672090-EE62DD5A-BD47-4434-882F-A63492263566 Q34744925-9217DB7B-CAFE-4B46-99F3-162D0CB2FDEE Q35073821-A606C54F-6638-48DC-B928-7A85370A6941 Q35171265-8C3E66A1-A47E-4A38-90BC-75759859225A Q35812522-5AF9CF4D-DDDD-4596-9B43-568B777A6EF9 Q35967276-402CD0DE-8055-4D2A-B42A-3FCB932235EE Q36155940-68C64ECA-4E35-4907-B6E8-7DD4B8E76775 Q36229010-E05B4D69-D5E0-44B6-BE88-EAD9106F0405 Q36313906-E921119F-76E6-4955-949B-DBAA833383C5 Q36924602-D78CAF49-1155-4CFC-BE16-C1CCF969D901

P2860

Field Evaluation of a Human Anthrax Vaccine

http://www.wikidata.org/entity/Q24554499

description

1962 nî lūn-bûn

@nan

1962 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1962 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1962年の論文

@ja

1962年論文

@yue

1962年論文

@zh-hant

1962年論文

@zh-hk

1962年論文

@zh-mo

1962年論文

@zh-tw

1962年论文

@wuu

name

Field Evaluation of a Human Anthrax Vaccine

@ast

Field Evaluation of a Human Anthrax Vaccine

@en

Field Evaluation of a Human Anthrax Vaccine

@nl

type

label

Field Evaluation of a Human Anthrax Vaccine

@ast

Field Evaluation of a Human Anthrax Vaccine

@en

Field Evaluation of a Human Anthrax Vaccine

@nl

prefLabel

Field Evaluation of a Human Anthrax Vaccine

@ast

Field Evaluation of a Human Anthrax Vaccine

@en

Field Evaluation of a Human Anthrax Vaccine

@nl

P1433

Q24554499-0B914671-E734-4A1A-AD7F-991C2D51CF80

P1476

Q24554499-84FE3301-D509-42A7-AA56-A46534482EAA

P2093

Q24554499-344BE4F2-0D0C-48AD-97F0-4A228D10264B

Q24554499-5C9F3892-91C9-435C-97B5-27B978121385

Q24554499-AF49D218-D5A0-47CA-8587-F654DC0A1F8D

Q24554499-DC996836-F25B-4B48-9F4A-7E23758B889E

Q24554499-FA3B261E-25C5-4536-AA40-D51472BF5E90

P2860

Q24554499-D79EE422-5AF8-4104-98C6-8BE63441C0C1

Q24554499-E3B0C54D-AA13-4AF0-8224-371B8134A36D

Q24554499-E57FBFBC-1D08-4CFF-ABD6-27D2AC5252A0

P304

Q24554499-96C7FEE1-166D-400D-9B3C-B3295C075642

P31

Q24554499-AFA581B5-450E-4AB2-9D59-69C968940F64

P3181

Q24554499-D1DD8FAC-3B9F-4777-85F8-FC7CE2CD0CE8

P356

Q24554499-2449AC70-24AA-46B7-9E8E-7CB239CE9327

P407

Q24554499-77913807-98BF-40C2-B5FF-C6EF80127171

P433

Q24554499-483C2C9C-CB0B-4A46-B6E9-9E1D3B42F912

P478

Q24554499-433686EE-1E7A-4D8B-9AF0-4AF43C96E336

P50

Q24554499-1D70C5B3-C802-45B1-8779-0CBAA19B60BE

P577

Q24554499-1AC466D6-13AC-4B21-B5EE-EF40B397EC99

P698

Q24554499-C6552002-D9B6-4288-8B30-F2DA1AD9602B

P932

Q24554499-E50C6124-B396-4713-9D21-156ACCFCAC0B

P3181

P356

P1433

American Journal of Public Health and the Nation's Health

P1476

Field Evaluation of a Human Anthrax Vaccine

@en

P2093

F R Fekety

http://www.w3.org/2001/XMLSchema#string

H Gold

http://www.w3.org/2001/XMLSchema#string

M Werrin

http://www.w3.org/2001/XMLSchema#string

N R Ingraham

http://www.w3.org/2001/XMLSchema#string

P S Brachman

http://www.w3.org/2001/XMLSchema#string

P2860

Studies on immunity in anthrax. II. In vitro elaboration of protective antigen by non-proteolytic mutants of Bacillus anthracis

Studies on immunity in anthrax. IV. Factors influencing elaboration of the protective antigen of bacillus antracis in chemically defined media.

Studies on immunity in anthrax. I. Variation in the serum T-agglutinin during anthrax infection in the rabbit.

P304

632-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5090659

http://www.w3.org/2001/XMLSchema#string

P356

10.2105/AJPH.52.4.632

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Stanley Plotkin

P577

1962-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18017912

http://www.w3.org/2001/XMLSchema#string

P932

1522900

http://www.w3.org/2001/XMLSchema#string